phase 2 vs triple agonist — genuinely asking which matters more
Long-ish post, sorry. tl;dr at the bottom.
I have been tracking retatrutide against triglycerides for 31 weeks because I could not find anyone who had. The correlation is weaker than I expected, which is itself mildly interesting given how confidently people link the two in here.
Caveats up front: one person, one lab, one assay, no control, and I changed my training in the middle of it, which was stupid.
tl;dr: probably real, definitely smaller than the threads imply, and not worth reorganising your week around.
best — the order this archive was captured in
Titration speed is a side-effect dial far more than an efficacy dial.
retatrutide is not approved anywhere for human use, posts must not read as instructions
phase 2 numbers are not maintenance numbers, cite the trial
Which trial arm and what was the n?
research use only, handling and analysis, not protocols
Disagree but this is the good kind of wrong — it is specific enough to be checked.
What was the dosing schedule in that arm?
Every time this gets posted it hits the front page and every time someone has to re-explain it.
Sceptical. If this were true we would see it reflected in the data and we do not.
[deleted]
triple agonism is glucagon, do not generalise
nobody should be giving this to anyone without extensive monitoring
Dose escalation on retatrutide is steeper and faster than on semaglutide. Do not assume the titration patterns transfer.
the 0.5mg arm is different from 0.25mg, results do not transfer
I am going to push back on this slightly.
the weight curves are unusually steep, which makes predicting individual response harder
the weight curves are unusually steep, which makes predicting individual response harder
Adding to this: dose escalation is doing more work than the comment implies.
TRIUMPH data is phase 2, not phase 3, smaller n and shorter
That is net peptide content, not purity. Different number, different meaning.
phase 2 numbers are not maintenance numbers, cite the trial
triple agonism is phase 2, do not generalise
Strongly agree. Heart rate escalation needs the actual data, not impressions.
Yeah, phase 2 retatrutide is interesting but it is not comparable to phase 3 compounds.
Small correction: the trial was 17 weeks, not 38. Does not change your point but people will quote it.
- 1Every time this gets posted it hits the front page and every time someone…7 comments in this branch · started by u/trialwatch_theo
- 2TRIUMPH data is phase 2, not phase 3, smaller n and shorter7 comments in this branch · started by u/jarno_cabrera